{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-270019","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.028255+00:00","generated_at":"2026-05-16T23:24:05.560434+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS","bullets":["Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.","FY2025 revenue guidance narrowed to $36M-$38M; combined 2026 with IRRAS expected $54M-$60M.","Signed agreement to acquire IRRAS Holdings; no purchase price disclosed.","New CAL preclinical facility operational; FDA 510(k) clearance for 1.5T PRISM Laser Therapy.","Active biopharma partners >60; plan to activate 35-40 specialized centers for cell/gene therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-270019","json":"https://secwatch.observer/filing/0001193125-25-270019.json","markdown":"https://secwatch.observer/filing/0001193125-25-270019.md","text":"https://secwatch.observer/filing/0001193125-25-270019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000119312525270019/0001193125-25-270019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000119312525270019/clpt-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:24:05.560434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}